Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mindset Pharma Equity Warrants Exp 15th April 2024 MSSTF


Primary Symbol: C.MSET.W

Healthcare
Mindset Pharma Inc is a drug discovery and development company focused on creating psychedelic medicines to treat neurological and psychiatric disorders.


CSE:MSET.W - Post by User

Mindset Pharma Equity Warrants Exp 15th April 2024
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1885)
•••
Post by Betteryear2on Mar 17, 2022 4:31pm
252 Views
Post# 34523218

Issues Letter to Shareholders CSE: MSET

Issues Letter to Shareholders CSE: MSETTORONTO, March 17, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset.

Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities